tiprankstipranks
Trending News
More News >

IDEAYA Biosciences Holds Annual Stockholders Meeting

Story Highlights
  • IDEAYA Biosciences focuses on precision medicine and immuno-oncology therapies.
  • At the 2025 Annual Meeting, key proposals on directors, auditors, and compensation were approved.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
IDEAYA Biosciences Holds Annual Stockholders Meeting

Don’t Miss TipRanks’ Half-Year Sale

IDEAYA Biosciences ( (IDYA) ) has provided an announcement.

On June 24, 2025, IDEAYA Biosciences held its Annual Meeting of Stockholders where three proposals were voted on. The election of two Class III directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and approval of executive compensation were addressed. The election saw Jeffrey L. Stein, Ph.D., and Scott W. Morrison nominated, with Stein receiving more votes. The ratification of the auditor was largely uncontested, and the executive compensation received a majority vote in favor, indicating shareholder support for the company’s leadership and financial oversight.

The most recent analyst rating on (IDYA) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

Spark’s Take on IDYA Stock

According to Spark, TipRanks’ AI Analyst, IDYA is a Neutral.

IDEAYA Biosciences’ stock score is primarily impacted by its financial performance challenges, including declining revenues and net losses. Positive technical indicators provide some support, indicating potential short-term momentum. However, the lack of profitability and valuation concerns weigh heavily on the overall score.

To see Spark’s full report on IDYA stock, click here.

More about IDEAYA Biosciences

IDEAYA Biosciences, Inc. operates in the biotechnology industry, focusing on the development of precision medicine and immuno-oncology therapies. The company is engaged in discovering and developing targeted therapeutics for cancer treatment, emphasizing synthetic lethality and direct targeting of oncogenic pathways.

Average Trading Volume: 1,433,738

Technical Sentiment Signal: Sell

Current Market Cap: $1.9B

For detailed information about IDYA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1